Financial reports
10-K
2023 FY
Annual report
15 Feb 24
10-Q
2023 Q3
Quarterly report
26 Oct 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
16 Feb 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
17 Feb 22
Current reports
8-K
Other Events
22 Feb 24
8-K
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
15 Feb 24
8-K
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
8-K
Blueprint Medicines Reports Third Quarter 2023 Results
26 Oct 23
8-K
Other Events
25 Aug 23
8-K
Blueprint Medicines Reports Second Quarter 2023 Results
2 Aug 23
8-K
Other Events
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 23
8-K
Entry into a Material Definitive Agreement
25 May 23
8-K
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
22 May 23
Registration and prospectus
S-8
Registration of securities for employees
16 Feb 24
S-8
Registration of securities for employees
17 Feb 23
424B5
Prospectus supplement for primary offering
17 Feb 23
S-3ASR
Automatic shelf registration
17 Feb 23
S-8
Registration of securities for employees
2 Aug 22
424B5
Prospectus supplement for primary offering
17 Feb 22
S-8
Registration of securities for employees
17 Feb 22
S-8
Registration of securities for employees
17 Feb 21
424B5
Prospectus supplement for primary offering
31 Jul 20
S-8
Registration of securities for employees
6 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEF 14A
Definitive proxy
29 Apr 19
Other
CT ORDER
Confidential treatment order
1 Jul 21
UPLOAD
Letter from SEC
11 Feb 21
CORRESP
Correspondence with SEC
14 Jan 21
UPLOAD
Letter from SEC
2 Dec 20
SEC STAFF
SEC staff action: Order
9 Apr 20
CT ORDER
Confidential treatment order
16 Mar 20
SEC STAFF
SEC staff action: Order
18 Feb 20
SEC STAFF
SEC staff action: Order
4 Feb 20
SEC STAFF
SEC staff action: Order
31 Jan 20
CT ORDER
Confidential treatment order
27 Sep 19
Ownership
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Apr 24
4
Michael Landsittel
1 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Jeffrey W. Albers
26 Mar 24
4
Jeffrey W. Albers
22 Mar 24
4
Michael Landsittel
19 Mar 24
4
Ariel Hurley
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Philina Lee
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24